argenx (ARGX) to Release Earnings on Thursday

argenx (NASDAQ:ARGX) will announce its earnings results before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.45). argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. The business had revenue of $417.84 million during the quarter, compared to analyst estimates of $378.60 million. During the same period in the previous year, the business posted ($0.70) earnings per share. On average, analysts expect argenx to post $-2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

argenx Price Performance

NASDAQ:ARGX traded up $4.28 during mid-day trading on Thursday, reaching $387.62. The company’s stock had a trading volume of 36,793 shares, compared to its average volume of 310,195. The company’s fifty day simple moving average is $384.46 and its two-hundred day simple moving average is $413.84. argenx has a twelve month low of $327.73 and a twelve month high of $550.76. The stock has a market cap of $23.04 billion, a P/E ratio of -74.75 and a beta of 0.67.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Robert W. Baird cut their price objective on argenx from $505.00 to $490.00 and set an “outperform” rating on the stock in a report on Friday, March 1st. Wolfe Research assumed coverage on argenx in a report on Thursday, February 15th. They issued a “peer perform” rating on the stock. Truist Financial raised their price objective on argenx from $370.00 to $440.00 and gave the stock a “buy” rating in a report on Tuesday, March 5th. JMP Securities reiterated a “market outperform” rating and set a $471.00 target price on shares of argenx in a report on Friday, March 22nd. Finally, HC Wainwright reiterated a “buy” rating and set a $451.00 target price on shares of argenx in a report on Thursday, April 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $528.16.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.